The use of computational QSAR analysis in the toxicological evaluation of a series of 2-pyridylcarboxamidrazone candidate anti-tuberculosis compounds.

[1]  M. Coleman,et al.  Synthesis and antimycobacterial activity of some heteroarylcarboxamidrazone derivatives. , 1998, Drug design and discovery.

[2]  S. Spielberg,et al.  Acetaminophen toxicity in human lymphocytes in vitro. , 1980, The Journal of pharmacology and experimental therapeutics.

[3]  A. Bøyum.  Isolation of lymphocytes, granulocytes and macrophages. , 1976, Scandinavian journal of immunology.

[4]  B. Petrini,et al.  Drug-resistant and multidrug-resistant tubercle bacilli. , 1999, International journal of antimicrobial agents.

[5]  S. Ferrini,et al.  The protective effects of N-acetyl-L-cysteine against methyl mercury embryotoxicity in mice. , 1993, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[6]  T. Djuretic.  Anti-tuberculosis drug resistance in Europe , 2000 .

[7]  D. Young.  Blueprint for the white plague , 1998, Nature.

[8]  E. Banfi,et al.  Synthesis and antimycobacterial activity of some 2-pyridinecarboxyamidrazone derivatives. , 1992, Farmaco.

[9]  J. G. Douglas,et al.  Pharmacokinetic Factors in the Modern Drug Treatment of Tuberculosis , 1999, Clinical pharmacokinetics.

[10]  T W Schultz,et al.  Structure-toxicity relationships for phenols to Tetrahymena pyriformis. , 1996, Chemosphere.

[11]  Eñaut Urrestarazu Ramos,et al.  Algal growth inhibition of Chlorella pyrenoidosa by polar narcotic pollutants: toxic cell concentrations and QSAR modeling , 1999 .

[12]  M. Coleman,et al.  A Comparison of the In‐vitro Toxicity of Sulphametrole and Sulphamethoxazole† , 1995 .

[13]  J. Walley,et al.  Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan , 2001, The Lancet.

[14]  U. Taitelman,et al.  N-acetylcysteine increases the glutathione content and protects rat alveolar type II cells against paraquat-induced cytotoxicity. , 1996, Toxicology letters.

[15]  C. Barry,et al.  New horizons in the treatment of tuberculosis. , 1997, Biochemical pharmacology.

[16]  F. Drobniewski.  Multiple-drug-resistant tuberculosis , 2000, The Lancet.

[17]  Alimuddin Zumla,et al.  A study of maternal mortality at the University Teaching Hospital, Lusaka, Zambia: the emergence of tuberculosis as a major non-obstetric cause of maternal death. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[18]  J. Timbrell,et al.  Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo. , 1980, The Journal of pharmacology and experimental therapeutics.

[19]  R. Jacobs.  Multiple-drug-resistant tuberculosis. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Mark S. Gordon,et al.  General atomic and molecular electronic structure system , 1993, J. Comput. Chem..

[21]  Eamonn F. Healy,et al.  Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model , 1985 .

[22]  Aninvestigation oftherole ofmetabolism indapsone-induced methaemoglobinaemia using atwocompartment invitro test system , 1990 .

[23]  S. Adams,et al.  Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. , 1999, The Journal of pharmacology and experimental therapeutics.

[24]  M. Coleman,et al.  Preliminary in vitro toxicological evaluation of a series of 2-pyridylcarboxamidrazone candidate anti-tuberculosis compounds III. , 1999, Environmental toxicology and pharmacology.

[25]  S. Flora,et al.  N‐acetyl‐l‐cysteine , 1993, Journal of cellular biochemistry. Supplement.

[26]  B. K. Park,et al.  An Investigation into the Haematological Toxicity of Structural Analogues of Dapsone In‐vivo and In‐vitro , 1991, The Journal of pharmacy and pharmacology.

[27]  De Cock Km,et al.  Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. , 1999 .

[28]  D. Billington,et al.  A new amidrazone derivative with antimycobacterial activity. , 2000, Acta crystallographica. Section C, Crystal structure communications.

[29]  M. F. Pereira,et al.  Anti-tuberculosis drug resistance in Portugal. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.